Leveragen Japan patent strengthens the company’s global intellectual property estate and reinforces its leadership in single-domain antibody discovery. Leveragen, Inc. announced the issuance of Japan Patent No. JP7799706 covering core innovations behind its proprietary Singularity Platform.
The patent protects foundational design principles that power the Singularity Suite, Leveragen’s portfolio of genetically engineered mouse models for single-domain antibody (sdAb) discovery. As a result, the company enhances long-term collaboration opportunities with pharmaceutical and biotechnology partners worldwide.
Why Single-Domain Antibodies Matter
Single-domain antibodies are increasingly important in modern biologics development. Due to their compact size, intrinsic stability, and modular architecture, sdAbs are highly adaptable.
For example, they are well suited for advanced therapeutic formats such as multispecific antibodies, antibody–drug conjugates (ADCs), mRNA-encoded antibodies, and cell and gene therapies. In contrast, conventional antibody formats may face structural, manufacturing, or delivery limitations in these applications.
How the Singularity Platform Advances sdAb Discovery
The Singularity Platform was engineered to overcome the limitations of conventional transgenic models. It uses targeted genome engineering and streamlined immune system architectures to improve discovery efficiency.
Across the Singularity Suite, each model features a minimalist humoral immune system. Consequently, the immune response is focused exclusively on heavy-chain antibodies. This design concentrates immune selection on single-domain formats and enables the generation of high-diversity, high-fidelity sdAbs with strong stability, solubility, and developability.
Singularity Sapiens and Fully Human sdAbs
Within the suite, Singularity Sapiens is optimized for fully human single-domain antibody discovery. Importantly, it eliminates the need for camelid immunization and downstream humanization.
The model generates heavy-chain antibodies from a complete human VH repertoire. This repertoire is precisely integrated into the endogenous mouse immunoglobulin heavy-chain locus. Therefore, researchers can achieve in vivo selection of fully human sdAbs under native regulatory control.
A Broad Suite of Species-Native Scaffolds
The Singularity Suite applies its system-level design principles across multiple species-native scaffolds. These include human VH, human Vκ, alpaca VHH, shark VNAR, dog VH, cat VH, and mouse VH.
As a result, partners gain flexible access to diverse single-domain antibody modalities within a unified discovery framework.
Global Intellectual Property Expansion
The issuance of Japan Patent No. JP7799706 independently validates the novelty of the Singularity Platform. Moreover, it reinforces Leveragen’s ability to protect the core innovations behind its discovery technologies.
Corresponding patent applications are currently pending in the United States, China, Europe, Canada, Australia, and additional jurisdictions. Therefore, the Leveragen Japan patent marks a key milestone in expanding the company’s global intellectual property footprint.
Dr. Weisheng Chen, Founder and Chief Executive Officer of Leveragen, stated that the Singularity Platform was developed as a scalable foundation for sdAb discovery. He emphasized that the Japan patent strengthens Leveragen’s position as a differentiated provider of fully human and species-native single-domain antibody discovery technologies.
Supporting Scalable Biologics Innovation
Integrated with Leveragen’s sequence-first, high-throughput workflows, the Singularity Suite enables efficient and reproducible generation of developable single-domain antibodies.
These platforms support applications across human therapeutics, diagnostics, and animal health. In addition, Leveragen offers flexible licensing and service-based partnership models to accelerate biologics innovation globally.
Overall, the Leveragen Japan patent reinforces the company’s commitment to advancing next-generation single-domain antibody discovery through protected, scalable platform technologies.
Read Also: Anti-PACAP Therapy: Slate Medicines Raises $130M to Advance Migraine Prevention
